Literature DB >> 24201163

Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib.

Siraj M Ali1, R Kathy Alpaugh2, Jamie K Buell1, Philip J Stephens1, Jian Qin Michael Yu3, Hong Wu2, Christine N Hiemstra1, Vincent A Miller1, Doron Lipson1, Gary A Palmer1, Jeffrey S Ross4, Massimo Cristofanilli5.   

Abstract

Entities:  

Keywords:  HER2; Inflammatory breast cancer; Lapatinib; Next-generation sequencing; Trastuzumab

Mesh：

Substances：

Year:  2013        PMID： 24201163     DOI： 10.1016/j.clbc.2013.09.010

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN： 1526-8209            Impact factor:   3.225


× No keyword cloud information.
  10 in total

Review 1.  Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies.

Authors:  Trang H Au; Kai Wang; David Stenehjem; Ignacio Garrido-Laguna
Journal:  J Gastrointest Oncol       Date:  2017-06

Review 2.  Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments.

Authors:  Daniel G Stover; Nikhil Wagle
Journal:  Curr Oncol Rep       Date:  2015-04       Impact factor: 5.075

3.  SCAMP3 Regulates EGFR and Promotes Proliferation and Migration of Triple-Negative Breast Cancer Cells through the Modulation of AKT, ERK, and STAT3 Signaling Pathways.

Authors:  Ariana Acevedo-Díaz; Beatriz M Morales-Cabán; Astrid Zayas-Santiago; Michelle M Martínez-Montemayor; Ivette J Suárez-Arroyo
Journal:  Cancers (Basel)       Date:  2022-06-05       Impact factor: 6.575

4.  Low-level constitutional mosaicism of a de novoBRCA1 gene mutation.

Authors:  E Friedman; N Efrat; L Soussan-Gutman; A Dvir; Y Kaplan; T Ekstein; K Nykamp; M Powers; M Rabideau; J Sorenson; S Topper
Journal:  Br J Cancer       Date:  2015-01-29       Impact factor: 7.640

5.  Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model.

Authors:  Lara Lacerda; Bisrat G Debeb; Daniel Smith; Richard Larson; Travis Solley; Wei Xu; Savitri Krishnamurthy; Yun Gong; Lawrence B Levy; Thomas Buchholz; Naoto T Ueno; Ann Klopp; Wendy A Woodward
Journal:  Breast Cancer Res       Date:  2015-03-20       Impact factor: 6.466

6.  Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients.

Authors:  Catherine Bingham; Sandra V Fernandez; Patricia Fittipaldi; Paul W Dempsey; Karen J Ruth; Massimo Cristofanilli; R Katherine Alpaugh
Journal:  Breast Cancer Res Treat       Date:  2017-03-07       Impact factor: 4.872

7.  EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand.

Authors:  Youri Hoogstrate; Wies Vallentgoed; Johan M Kros; Iris de Heer; Maurice de Wit; Marica Eoli; Juan Manuel Sepulveda; Annemiek M E Walenkamp; Jean-Sebastien Frenel; Enrico Franceschi; Paul M Clement; Micheal Weller; Martin E van Royen; Peter Ansell; Jim Looman; Earle Bain; Marie Morfouace; Thierry Gorlia; Vassilis Golfinopoulos; Martin van den Bent; Pim J French
Journal:  Neurooncol Adv       Date:  2019-12-09

8.  Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas.

Authors:  Ya Gao; Wies R Vallentgoed; Pim J French
Journal:  Cancers (Basel)       Date:  2018-12-04       Impact factor: 6.639

9.  Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression.

Authors:  Ivette J Suárez-Arroyo; Tiffany J Rios-Fuller; Yismeilin R Feliz-Mosquea; Mercedes Lacourt-Ventura; Daniel J Leal-Alviarez; Gerónimo Maldonado-Martinez; Luis A Cubano; Michelle M Martínez-Montemayor
Journal:  J Cancer       Date:  2016-02-05       Impact factor: 4.207

10.  Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors.

Authors:  Maurice de Wit; Ya Gao; Darlene Mercieca; Iris de Heer; Bart Valkenburg; Martin E van Royen; Joachim Aerts; Peter Sillevis Smitt; Pim French
Journal:  EBioMedicine       Date:  2020-06-05       Impact factor: 8.143
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.